{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/353606760"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "Olaparib is an investigational orally active poly-ADP ribose polymerase (PARP) inhibitor being developed by AstraZeneca treating various tumor types including BRCA-mutated breast and ovarian cancers." ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "biopharminternational.com" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/452235302"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/353606760" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/452419941"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/353606760"] } } }
